Summary
Despite advances in immunotherapy for metastatic non-small cell lung cancer (NSCLC), a significant proportion of patients do not respond to immune checkpoint inhibitors (ICIs). Identifying effective prognostic biomarkers that are independent of squamous and nonsquamous histology is critical for optimizing treatment strategies in NSCLC. Interferon gamma (IFNG) has emerged as a potential marker for predicting immunotherapy outcomes due to its role in immune modulation.